152 related articles for article (PubMed ID: 28798985)
1. NanoString-based breast cancer risk prediction for women with sclerosing adenosis.
Winham SJ; Mehner C; Heinzen EP; Broderick BT; Stallings-Mann M; Nassar A; Vierkant RA; Hoskin TL; Frank RD; Wang C; Denison LA; Vachon CM; Frost MH; Hartmann LC; Aubrey Thompson E; Sherman ME; Visscher DW; Degnim AC; Radisky DC
Breast Cancer Res Treat; 2017 Nov; 166(2):641-650. PubMed ID: 28798985
[TBL] [Abstract][Full Text] [Related]
2. Gene signature model for breast cancer risk prediction for women with sclerosing adenosis.
Degnim AC; Nassar A; Stallings-Mann M; Keith Anderson S; Oberg AL; Vierkant RA; Frank RD; Wang C; Winham SJ; Frost MH; Hartmann LC; Visscher DW; Radisky DC
Breast Cancer Res Treat; 2015 Aug; 152(3):687-94. PubMed ID: 26202055
[TBL] [Abstract][Full Text] [Related]
3. Development of Malignancy-Risk Gene Signature Assay for Predicting Breast Cancer Risk.
Sun J; Chen DT; Li J; Sun W; Yoder SJ; Mesa TE; Wloch M; Roetzheim R; Laronga C; Lee MC
J Surg Res; 2020 Jan; 245():153-162. PubMed ID: 31419640
[TBL] [Abstract][Full Text] [Related]
4. Ki-67 expression in sclerosing adenosis and adjacent normal breast terminal ductal lobular units: a nested case-control study from the Mayo Benign Breast Disease Cohort.
Nassar A; Hoskin TL; Stallings-Mann ML; Degnim AC; Radisky DC; Frost MH; Vierkant RA; Hartmann LC; Visscher DW
Breast Cancer Res Treat; 2015 May; 151(1):89-97. PubMed ID: 25863475
[TBL] [Abstract][Full Text] [Related]
5. Sclerosing adenosis and risk of breast cancer.
Visscher DW; Nassar A; Degnim AC; Frost MH; Vierkant RA; Frank RD; Tarabishy Y; Radisky DC; Hartmann LC
Breast Cancer Res Treat; 2014 Feb; 144(1):205-12. PubMed ID: 24510013
[TBL] [Abstract][Full Text] [Related]
6. Model for individualized prediction of breast cancer risk after a benign breast biopsy.
Pankratz VS; Degnim AC; Frank RD; Frost MH; Visscher DW; Vierkant RA; Hieken TJ; Ghosh K; Tarabishy Y; Vachon CM; Radisky DC; Hartmann LC
J Clin Oncol; 2015 Mar; 33(8):923-9. PubMed ID: 25624442
[TBL] [Abstract][Full Text] [Related]
7. Invasive breast cancer risk in women with sclerosing adenosis.
Jensen RA; Page DL; Dupont WD; Rogers LW
Cancer; 1989 Nov; 64(10):1977-83. PubMed ID: 2804888
[TBL] [Abstract][Full Text] [Related]
8. Breast carcinoma in sclerosing adenosis: a clinicopathological and immunophenotypical analysis on 206 lesions.
Yu BH; Tang SX; Xu XL; Cheng YF; Bi R; Shui RH; Tu XY; Lu HF; Zhou XY; Yang WT
J Clin Pathol; 2018 Jun; 71(6):546-553. PubMed ID: 29436376
[TBL] [Abstract][Full Text] [Related]
9. A formalin-fixed paraffin-embedded (FFPE)-based prognostic signature to predict metastasis in clinically low risk stage I/II microsatellite stable colorectal cancer.
Low YS; Blöcker C; McPherson JR; Tang SA; Cheng YY; Wong JYS; Chua C; Lim TKH; Tang CL; Chew MH; Tan P; Tan IB; Rozen SG; Cheah PY
Cancer Lett; 2017 Sep; 403():13-20. PubMed ID: 28624625
[TBL] [Abstract][Full Text] [Related]
10. DNA methylation array analysis identifies breast cancer associated RPTOR, MGRN1 and RAPSN hypomethylation in peripheral blood DNA.
Tang Q; Holland-Letz T; Slynko A; Cuk K; Marme F; Schott S; Heil J; Qu B; Golatta M; Bewerunge-Hudler M; Sutter C; Surowy H; Wappenschmidt B; Schmutzler R; Hoth M; Bugert P; Bartram CR; Sohn C; Schneeweiss A; Yang R; Burwinkel B
Oncotarget; 2016 Sep; 7(39):64191-64202. PubMed ID: 27577081
[TBL] [Abstract][Full Text] [Related]
11. A multi-center prospective cohort study of benign breast disease and risk of subsequent breast cancer.
Kabat GC; Jones JG; Olson N; Negassa A; Duggan C; Ginsberg M; Kandel RA; Glass AG; Rohan TE
Cancer Causes Control; 2010 Jun; 21(6):821-8. PubMed ID: 20084540
[TBL] [Abstract][Full Text] [Related]
12. Standardized measures of lobular involution and subsequent breast cancer risk among women with benign breast disease: a nested case-control study.
Figueroa JD; Pfeiffer RM; Brinton LA; Palakal MM; Degnim AC; Radisky D; Hartmann LC; Frost MH; Stallings Mann ML; Papathomas D; Gierach GL; Hewitt SM; Duggan MA; Visscher D; Sherman ME
Breast Cancer Res Treat; 2016 Aug; 159(1):163-72. PubMed ID: 27488681
[TBL] [Abstract][Full Text] [Related]
13. The Genomic Grade Assay Compared With Ki67 to Determine Risk of Distant Breast Cancer Recurrence.
Ignatiadis M; Azim HA; Desmedt C; Veys I; Larsimont D; Salgado R; Lyng MB; Viale G; Leyland-Jones B; Giobbie-Hurder A; Kammler R; Dell'Orto P; Rothé F; Laïos I; Ditzel HJ; Regan MM; Piccart M; Michiels S; Sotiriou C
JAMA Oncol; 2016 Feb; 2(2):217-24. PubMed ID: 26633571
[TBL] [Abstract][Full Text] [Related]
14. A Novel 18-Marker Panel Predicting Clinical Outcome in Breast Cancer.
Biermann J; Nemes S; Parris TZ; Engqvist H; Rönnerman EW; Forssell-Aronsson E; Steineck G; Karlsson P; Helou K
Cancer Epidemiol Biomarkers Prev; 2017 Nov; 26(11):1619-1628. PubMed ID: 28877888
[No Abstract] [Full Text] [Related]
15. Breast cancer risk prediction in women aged 35-50 years: impact of including sex hormone concentrations in the Gail model.
Clendenen TV; Ge W; Koenig KL; Afanasyeva Y; Agnoli C; Brinton LA; Darvishian F; Dorgan JF; Eliassen AH; Falk RT; Hallmans G; Hankinson SE; Hoffman-Bolton J; Key TJ; Krogh V; Nichols HB; Sandler DP; Schoemaker MJ; Sluss PM; Sund M; Swerdlow AJ; Visvanathan K; Zeleniuch-Jacquotte A; Liu M
Breast Cancer Res; 2019 Mar; 21(1):42. PubMed ID: 30890167
[TBL] [Abstract][Full Text] [Related]
16. A methodological study of genome-wide DNA methylation analyses using matched archival formalin-fixed paraffin embedded and fresh frozen breast tumors.
Espinal AC; Wang D; Yan L; Liu S; Tang L; Hu Q; Morrison CD; Ambrosone CB; Higgins MJ; Sucheston-Campbell LE
Oncotarget; 2017 Feb; 8(9):14821-14829. PubMed ID: 28118602
[TBL] [Abstract][Full Text] [Related]
17. Predicting risk of breast cancer in postmenopausal women by hormone receptor status.
Chlebowski RT; Anderson GL; Lane DS; Aragaki AK; Rohan T; Yasmeen S; Sarto G; Rosenberg CA; Hubbell FA;
J Natl Cancer Inst; 2007 Nov; 99(22):1695-705. PubMed ID: 18000216
[TBL] [Abstract][Full Text] [Related]
18. Breast Density and Benign Breast Disease: Risk Assessment to Identify Women at High Risk of Breast Cancer.
Tice JA; Miglioretti DL; Li CS; Vachon CM; Gard CC; Kerlikowske K
J Clin Oncol; 2015 Oct; 33(28):3137-43. PubMed ID: 26282663
[TBL] [Abstract][Full Text] [Related]
19. Expression Concordance of 325 Novel RNA Biomarkers between Data Generated by NanoString nCounter and Affymetrix GeneChip.
Delmonico L; Attiya S; Chen JW; Obenauer JC; Goodwin EC; Fournier MV
Dis Markers; 2019; 2019():1940347. PubMed ID: 31217830
[TBL] [Abstract][Full Text] [Related]
20. Development and verification of the PAM50-based Prosigna breast cancer gene signature assay.
Wallden B; Storhoff J; Nielsen T; Dowidar N; Schaper C; Ferree S; Liu S; Leung S; Geiss G; Snider J; Vickery T; Davies SR; Mardis ER; Gnant M; Sestak I; Ellis MJ; Perou CM; Bernard PS; Parker JS
BMC Med Genomics; 2015 Aug; 8():54. PubMed ID: 26297356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
